At a pharmacological level, it is largely unknown to what extent medicines impact the activity of antioxidative enzymes such as Glutathione Peroxidase 1 (GPx1) which are involved in the pathogenesis of COPD [5–7]. This evidence concerns the gene GPX1 and chronic obstructive pulmonary disease.